Mostrando ítems 1-9 de 9
Multiple recombinant events in human T-cell Leukemia virus Type 1: complete sequences of recombinant African strains
(Emerging Microbes and Infections, 2020-01-01)
Africa is the largest endemic area for HTLV-1, with many molecular genotypes. We previously demonstrated that some strains from North Africa (a-NA clade) originated from a recombinant event between Senegalese and West ...
Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions
(AIDS Reviews, 2020-01)
Human immunodeficiency virus type 2 (HIV-2) was isolated in AIDS patients in 1986. Around 1-2 million people are infected worldwide. The virus is less transmissible than HIV-1, being sexual contacts the most frequent route ...
HTLV-1 infection and health outcomes
(The Lancet Infectious Diseases, 2020-04)
The meta-analysis published by Gill Schierhout and colleagues1 reported an increased relative risk of premature death in individuals infected with HTLV-1 compared with individuals not infected with HTLV-1 (RR 1·57, 95% CI ...
Tough requirements for new antiretroviral drugs
(The Lancet HIV, 2020-03)
Medical and social attention to HIV infection has declined globally and is increasingly focused on developing regions, where the epidemic is still largely uncontrolled. In North America and western Europe, AIDS is rarely ...
Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2
(Journal of Infectious Diseases, 2020-06)
Background: HIV-1 and HIV-2 differ in their antiretroviral (ARV) susceptibilities and drug resistance mutations (DRMs). Methods: We analyzed published HIV-2 pol sequences to identify HIV-2 treatment-selected mutations ...
Hospital admissions in individuals with HTLV-1 infection in Spain
OBJECTIVE: To examine the clinical burden and disease spectrum, as well as time trends for human T-cell leukemia virus type 1 (HTLV-1) and HTLV type 2 (HTLV-2) hospital admissions. DESIGN: Retrospective, observational study ...
Long-acting antiretroviral therapy
(Nature Materials, 2020-08-01)
Nanoformulations of cabotegravir prodrugs have been developed to prolong the pharmacokinetics of the antiretroviral agent. They can be present in the plasma of mice and non-human primates for a year following a single injection.
Advances in hepatitis B therapeutics
(Therapeutic Advances in Infectious Disease, 2020-10)
Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...
COVID-19 Comes 40 Years After AIDS - Any Lesson?
(AIDS Reviews, 2020-06)
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic ...